Briacell Therapeutics Corp
BCTX6.800USD
0.000
Close 04/24, 16:00（ET）Quotes delayed by 15 min
20.04MMarket Cap
LossP/E TTM
More Details of Briacell Therapeutics Corp Company
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. Bria-IMT, its Phase 3 lead candidate, is a patented, off-the-shelf, cell-based, targeted immunotherapy that activates the patient’s immune system to specifically kill cancer cells without harming other cells. The Company is advancing its Bria-IMT targeted immunotherapy in combination with an immune check point inhibitor (Retifanlimab) in a pivotal Phase 3 study in metastatic breast cancer. It is also developing personalized off-the-shelf immunotherapies, Bria-OTS and Bria-OTS+, which provides a platform technology to develop personalized off-the-shelf immunotherapies for numerous types of cancer, and a soluble CD80 protein therapeutic which act both as a stimulator of the immune system, as well as an immune checkpoint inhibitor. Its pipeline also includes Bria-IMT + CPI, Bria-BRES/BRES+, Bria-PROS+, Bria-LUNG+ and Bria-MEL+.
Company Info
Company codeBCTX
Company nameBriacell Therapeutics Corp
IPO dateOct 12, 2006
Founded at2006
CEODr. William V. Williams, M.D.
Number of employees17
Security typeOrdinary Share
Fiscal year-endOct 12
AddressSuite 300 - Bellevue Centre, 235 -15th Street
CityWEST VANCOUVER
Stock exchangeNASDAQ Capital Market Consolidated
CountryCanada
Postal codeV7T 2X1
Phone16049211810
Websitehttps://briacell.com/
Company codeBCTX
IPO dateOct 12, 2006
Founded at2006
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. William V. Williams, M.D.
Dr. William V. Williams, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
10.81K
+2.10%
Mr. Jamieson Bondarenko
Mr. Jamieson Bondarenko
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
10.77K
+34.77%
Mr. Vaughn C. Embro-pantalony, CPA
Mr. Vaughn C. Embro-pantalony, CPA
Independent Director
Independent Director
1.19K
+22.93%
Mr. Gadi Levin
Mr. Gadi Levin
Chief Financial Officer, Corporate Secretary
Chief Financial Officer, Corporate Secretary
187.00
--
Mr. Martin E. Schmieg, CPA
Mr. Martin E. Schmieg, CPA
Independent Director
Independent Director
--
--
Dr. Rebecca A. Taub, M.D.
Dr. Rebecca A. Taub, M.D.
Independent Director
Independent Director
--
-100.00%
Dr. Giuseppe Del Priore, M.D.
Dr. Giuseppe Del Priore, M.D.
Chief Medical Officer
Chief Medical Officer
--
-100.00%
Dr. Jane A. Gross, Ph.D.
Dr. Jane A. Gross, Ph.D.
Independent Director
Independent Director
--
-100.00%
Dr. Miguel A. Lopez-Lago
Dr. Miguel A. Lopez-Lago
Chief Scientific Officer
Chief Scientific Officer
--
-100.00%
Name
Name/Position
Position
Shareholding
Change
Dr. William V. Williams, M.D.
Dr. William V. Williams, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
10.81K
+2.10%
Mr. Jamieson Bondarenko
Mr. Jamieson Bondarenko
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
10.77K
+34.77%
Mr. Vaughn C. Embro-pantalony, CPA
Mr. Vaughn C. Embro-pantalony, CPA
Independent Director
Independent Director
1.19K
+22.93%
Mr. Gadi Levin
Mr. Gadi Levin
Chief Financial Officer, Corporate Secretary
Chief Financial Officer, Corporate Secretary
187.00
--
Mr. Martin E. Schmieg, CPA
Mr. Martin E. Schmieg, CPA
Independent Director
Independent Director
--
--
Dr. Rebecca A. Taub, M.D.
Dr. Rebecca A. Taub, M.D.
Independent Director
Independent Director
--
-100.00%
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholder
Update time: Sun, Feb 23
Update time: Sun, Feb 23
Shareholder Statistics
Type
Shareholder Statistics
Shareholder
Proportion
3I Management LLC
9.95%
L5 Capital Inc.
4.69%
Lynwood Capital Management Inc.
2.87%
Copia Fund (Cayman) LP
1.47%
Williams (William V)
0.29%
Other
80.73%
Shareholder Statistics
Shareholder
Proportion
3I Management LLC
9.95%
L5 Capital Inc.
4.69%
Lynwood Capital Management Inc.
2.87%
Copia Fund (Cayman) LP
1.47%
Williams (William V)
0.29%
Other
80.73%
Type
Shareholder
Proportion
Family Office
9.95%
Corporation
6.16%
Investment Advisor/Hedge Fund
2.89%
Investment Advisor
0.67%
Individual Investor
0.62%
Research Firm
0.47%
Hedge Fund
0.03%
Bank and Trust
0.01%
Other
79.19%
Institutional Shareholding
Update time: Sat, Feb 22
Update time: Sat, Feb 22
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q1
65
403.53K
10.88%
-198.25K
2024Q4
65
403.53K
10.88%
-198.25K
2024Q3
64
441.30K
30.40%
+131.88K
2024Q2
63
437.48K
31.09%
+121.43K
2024Q1
62
332.09K
21.52%
-17.16K
2023Q4
67
402.86K
34.69%
+35.57K
2023Q3
74
369.20K
35.11%
-158.11K
2023Q2
84
434.95K
41.59%
-338.84K
2023Q1
83
423.04K
40.96%
-355.97K
2022Q4
78
427.52K
41.39%
-334.82K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
3I Management LLC
369.00K
9.95%
+369.00K
--
Feb 05, 2025
L5 Capital Inc.
174.03K
4.69%
+4.50K
+2.65%
Dec 10, 2024
Lynwood Capital Management Inc.
106.52K
2.87%
+1.14K
+1.08%
Mar 31, 2024
Copia Fund (Cayman) LP
54.56K
1.47%
+54.56K
--
Dec 29, 2023
Williams (William V)
10.81K
0.29%
+222.00
+2.10%
Dec 09, 2024
Bondarenko (Jamieson)
10.77K
0.29%
+2.78K
+34.77%
Dec 09, 2024
Bank Vontobel AG
7.33K
0.2%
+2.00K
+37.50%
Dec 31, 2024
Group One Trading, L.P.
4.53K
0.12%
+2.00K
+79.18%
Dec 31, 2024
Cantor Fitzgerald, L.P
3.73K
0.1%
+3.73K
--
Dec 31, 2024
Susquehanna International Group, LLP
3.37K
0.09%
+2.45K
+263.97%
Dec 31, 2024
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Jan 03, 2025
Merger
15<1
Jan 03, 2025
Merger
15<1
Jan 03, 2025
Merger
15<1
Jan 03, 2025
Merger
15<1
Date
Type
Ratio
Jan 03, 2025
Merger
15<1
Jan 03, 2025
Merger
15<1
Jan 03, 2025
Merger
15<1
Jan 03, 2025
Merger
15<1